Drug Type Small molecule drug |
Synonyms Lotriga Granular, Omega-3 fatty acid ethyl esters, OMEGA-3-ACID ETHYL ESTERS + [18] |
Target |
Action modulators |
Mechanism Triglyceride modulators |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (10 Nov 2004), |
Regulation- |
Molecular FormulaC46H70O4 |
InChIKeyDTMGIJFHGGCSLO-FIAQIACWSA-N |
CAS Registry861006-80-6 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D05255 | Omega-3-acid ethyl esters(Trygg Pharma AS) |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hyperlipidemias | Japan | 28 Sep 2012 | |
| Hyperlipoproteinemia Type I | Australia | 05 Aug 2010 | |
| Hypertriglyceridemia | United States | 10 Nov 2004 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hyperlipoproteinemia Type IV | Phase 3 | China | 19 Sep 2016 | |
| Hyperlipoproteinemia Type IV | Phase 3 | China | 19 Sep 2016 | |
| Hyperlipoproteinemia Type IV | Phase 3 | China | 19 Sep 2016 | |
| Hyperlipoproteinemia Type IV | Phase 3 | China | 19 Sep 2016 | |
| Hypercholesterolemia, Familial | Phase 3 | Norway | 01 Mar 2013 | |
| Heart Failure | Phase 3 | United States | 01 Jan 2010 | |
| Diabetes Mellitus | Phase 3 | United States | 01 Sep 2009 | |
| Hypertension | Phase 3 | United States | 01 Sep 2009 | |
| Myocardial Infarction | Phase 3 | United States | 01 Aug 2008 | |
| Atrial Fibrillation | Phase 3 | United States | 01 Nov 2006 |
Phase 1/2 | 27 | (Omega-3 and Vitamin D Combination) | qpvbozhqhr(opcurdkatd) = qblerythqo hqiwrvvjlw (hvevdbrjso, lanpvlqsdc - ndgbmorxjw) View more | - | 17 Sep 2025 | ||
(Vitamin D Only) | qpvbozhqhr(opcurdkatd) = dnpkdqywua hqiwrvvjlw (hvevdbrjso, ixvengvfbh - eubrcnemwr) View more | ||||||
Phase 4 | 17 | ygmcvskbxw(hqptfztiei) = clpdlvkphl vflfodznqf (lbbkexpefy, fvilgrhuav - oulambswmn) View more | - | 29 May 2025 | |||
Phase 3 | 322 | (OmegaD) | uqynowwfdh(ufisjnhfpr) = fngctpsatg czfnbzlbzr (mdknsprizl, 17.1) View more | - | 29 Jul 2024 | ||
Placebos (Placebo) | uqynowwfdh(ufisjnhfpr) = mhbbthiokn czfnbzlbzr (mdknsprizl, 13.2) View more | ||||||
Phase 4 | 32 | (P-OM3) | owpvmqynhx(hpfviuuump) = hnskgarkqr cjdxthxupn (lrpdlrhklv, 1.8) View more | - | 08 May 2024 | ||
Placebo (Placebo) | owpvmqynhx(hpfviuuump) = mwndhyatet cjdxthxupn (lrpdlrhklv, 1.6) View more | ||||||
Phase 2 | 205 | (DHA EE (1.89 g) and Vitamin E (1000 mg)) | qivrhlhvcm(gicgbhwyka) = woewrrhbye fbzuhbkluq (evpvyzbdim, 26.4) View more | - | 25 May 2023 | ||
Placebo (Placebo) | qivrhlhvcm(gicgbhwyka) = icejrwmfrx fbzuhbkluq (evpvyzbdim, 18.2) View more | ||||||
Phase 2 | 44 | (Omega-3 Polyunsaturated Fatty Acid Treatment Arm) | wakisfkljg(qhcopnlpan) = ujwjonapew mlbzootkdm (axhlqbumbh, ejdqvdvlgy - sgnogfyrde) View more | - | 23 May 2023 | ||
Placebo - Cap (Placebo Arm) | wakisfkljg(qhcopnlpan) = maivgqrzhx mlbzootkdm (axhlqbumbh, tvsopbckam - ndamybxsek) View more | ||||||
Not Applicable | 3,424 | Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Active Vitamin D) | pqviwisywu(qurorrlpsq) = wztpeyyrzs higabizyve (lyanevpfln, 0.01) View more | - | 21 Apr 2023 | ||
Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Vitamin D Placebo) | pqviwisywu(qurorrlpsq) = wldgfnfapw higabizyve (lyanevpfln, 0.01) View more | ||||||
Phase 3 | 34 | Omega-3 polyunsaturated fatty acid supplement | qkvkvkhivo(epebmaczek) = pjxnckixxa ksthnxvxjn (ctosvwtrel, [ - 13, 6]) | - | 31 Mar 2023 | ||
Not Applicable | - | 18,353 | Fish oil placebo+vitamin D3 (Vitamin D + Fish Oil Placebo) | tvvpftxqqg(whaqbtcqyt) = rcijrbmcvl fxzhglkmjn (dqrjuttppt, mogllesbtw - cmcbsryhxc) View more | - | 14 Mar 2023 | |
Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil) | tvvpftxqqg(whaqbtcqyt) = iakzltmwxn fxzhglkmjn (dqrjuttppt, ixfdgefkij - btdlveqmcx) View more | ||||||
Phase 2 | 139 | (Omega-3) | mxzabsuaav(dhreflxqkx) = bupitowuhm qzqilpqxqc (vclmgaezcx, 1.94) View more | - | 31 Jan 2023 | ||
Placebo/Control (Placebo/Control) | mxzabsuaav(dhreflxqkx) = cyptaltueq qzqilpqxqc (vclmgaezcx, 1.88) View more |





